慢性成人原发免疫性血小板减少症的治疗进展

曹璇; 杨仁池

doi:10.13201/j.issn.1004-2806.2021.01.017

慢性成人原发免疫性血小板减少症的治疗进展

曹璇,
杨仁池^,

- 中国医学科学院血液病医院(中国医学科学院血液学研究所)实验血液学国家重点实验室国家血液系统疾病临床医学研究中心(天津, 300020)
基金项目:
国家自然科学基金(No:81670118)

天津市自然科学基金(No:18JCZDJC35000)

详细信息

通讯作者: 杨仁池,E-mail:rcyang65@163.com

中图分类号: R558.2

收稿日期: 2020-06-23

Progress in the treatment of chronic primary immune thrombocytopenia in adults

CAO Xuan,
YANG Renchi^,

More Information

Corresponding author: YANG Renchi, E-mail: rcyang65@163.com

Received Date: 23 June 2020

摘要

摘要: 原发免疫性血小板减少症（immune thrombocytopenia,ITP）是一种获得性自身免疫性疾病,其特征在于血小板破坏过多和（或）血小板生成受损导致血小板计数低;发生率为（2～5）/10万人,可以是孤立的原发疾病,也可以由其他疾病继发产生。ITP按疾病持续时间可分为:新诊断（0～3个月）,持续（3～12个月）或慢性（＞12个月）。ITP是一种异质性疾病,临床症状多样,诊断需排除引起血小板减少的其他疾病。ITP自发缓解率与年龄有关,＜1岁患者的1年缓解率为74%,1～6岁患者的1年缓解率为67%,10～20岁患者的1年缓解率为62%。成人的自然史研究较少,据报道有20%～45%的患者在6个月内完全缓解。
- 原发免疫性血小板减少症 /
- 总体反应 /
- 部分反应 /
- 不良事件
Abstract: In recent years, great progress has been made in the treatment of chronic primary immune thrombocytopenia(ITP), and drugs targeting the pathogenesis of ITP have been approved for marketing. In this paper, the effectiveness and long-term safety of the current new therapy for chronic ITP patients at home and abroad were reviewed for reference.
- primary immune thrombocytopenia /
- overall response /
- partial response /
- adverse event

HTML全文

参考文献(36)

[1]	Provan D,Arnold DM,Bussel JB,et al.Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood Adv,2019,3(22):3780-3817.
[2]	Neunert C,Terrell DR,Arnold DM,et al.American Society of Hematology 2019 guidelines for immune thrombocytopenia[J].Blood Adv,2019,3(23):3829-3866.
[3]	Ghanima W,Cooper N,Rodeghiero F,et al.Thrombopoietin receptor agonists:ten years later[J].Haematologica,2019,104(6):1112-1123.
[4]	Newland A,Godeau B,Priego V,et al.Remission and platelet responses with romiplostim in primary immune thrombocytopenia:final results from a phase 2 study[J].Br J Haematol,2016,172(2):262-273.
[5]	González-López TJ,Pascual C,Álvarez-Román MT,et al.Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia[J].Am J Hematol,2015,90(3):E40-E43.
[6]	Kuter DJ,Bussel JB,Newland A,et al.Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia:safety and efficacy[J].Br J Haematol,2013,161(3):411-423.
[7]	Wong RSM,Saleh MN,Khelif A,et al.Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag:final results of the EXTEND study[J].Blood,2017,130(23):2527-2536.
[8]	Wang L,Gao Z,Chen XP,et al.Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia:A systematic review and meta-analysis[J].Sci Rep,2016,6:39003.
[9]	Puavilai T,Thadanipon K,Rattanasiri S,et al.Treatment efficacy for adult persistent immune thrombocytopenia:a systematic review and network meta-analysis[J].Br J Haematol,2020,188(3):450-459.
[10]	Jurczak W,Chojnowski K,Mayer J,et al.Phase 3 randomised study of avatrombopag,a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia[J].Br J Haematol,2018,183(3):479-490.
[11]	Khellaf M,Viallard JF,Hamidou M,et al.A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia[J].Haematologica,2013,98(6):881-887.
[12]	Lakhwani S,Perera M,Fernández-Fuertes F,et al.Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients:A retrospective collaborative survey involving 4 Spanish centres[J].Eur J Haematol,2017,99(4):372-377.
[13]	Cantoni S,Carpenedo M,Mazzucconi MG,et al.Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients:A retrospective collaborative survey from Italian hematology centers[J].Am J Hematol,2018,93(1):58-64.
[14]	Marangon M,Vianelli N,Palandri F,et al.Rituximab in immune thrombocytopenia:gender,age,and response as predictors of long-term response[J].Eur J Haematol,2017,98(4):371-377.
[15]	Deshayes S,Khellaf M,Zarour A,et al.Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia:Results at 5-years from the French prospective registry ITP-ritux[J].Am J Hematol,2019,94(12):1314-1324.
[16]	Moore DC,Gebru T,Muslimani A.Fostamatinib for the treatment of immune thrombocytopenia in adults[J].Am J Health Syst Pharm,2019,76(11):789-794.
[17]	Bussel J,Arnold DM,Grossbard E,et al.Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia:Results of two phase 3,randomized,placebo-controlled trials[J].Am J Hematol,2018,93(7):921-930.
[18]	Bussel JB,Arnold DM,Boxer MA,et al.Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program[J].Am J Hematol,2019,94(5):546-553.
[19]	Zhou H,Hou Y,Liu X,et al.Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia[J].Thromb Haemost,2015,113(5):1021-1034.
[20]	Zhou H,Qin P,Liu Q,et al.A prospective,multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia[J].Am J Hematol,2019,94(12):1374-1381.
[21]	孙艳花,冉学红,高梅,等.低剂量地西他滨治疗成人难治复发原发免疫性血小板减少症的临床研究[J].临床血液学杂志,2020,33(11):759-761,766.
[22]	Feng FE,Feng R,Wang M,et al.Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia:a multicentre,randomised,open-label,phase 2 trial[J].Lancet Haematol,2017,4(10):e487-e496.
[23]	Qi A,Zhou H,Zhou Z,et al.Telomerase activity increased and telomere length shortened in peripheral blood cells from patients with immune thrombocytopenia[J].J Clin Immunol,2013,33(3):577-585.
[24]	Witkowski M,Witkowska M,Robak T.Autoimmune thrombocytopenia:Current treatment options in adults with a focus on novel drugs[J].Eur J Haematol,2019,103(6):531-541.
[25]	Liu W,Gu X,Fu R,et al.The Effect of Danazol in Primary Immune Thrombocytopenia:An Analysis of a Large Cohort From a Single Center in China[J].Clin Appl Thromb Hemost,2016,22(8):727-733.
[26]	Zhu X,Wang Y,Jiang Q,et al.All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop[J].Haematologica,2019,104(8):1661-1675.
[27]	Dai L,Zhang R,Wang Z,et al.Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia[J].Thromb Res,2016,140:73-80.
[28]	Cooper N,Ghanima W.Immune Thrombocytopenia[J].N Engl J Med,2019,381(10):945-955.
[29]	Guan Y,Wang S,Xue F,et al.Long-term results of splenectomy in adult chronic immune thrombocytopenia[J].Eur J Haematol,2017,98(3):235-241.
[30]	Vikse J,Sanna B,Henry BM,et al.The prevalence and morphometry of an accessory spleen:A meta-analysis and systematic review of 22,487 patients[J].Int J Surg,2017,45:18-28.
[31]	Mahévas M,Gerfaud-Valentin M,Moulis G,et al.Characteristics,outcome,and response to therapy of multirefractory chronic immune thrombocytopenia[J].Blood,2016,128(12):1625-1630.
[32]	侯明.免疫性血小板减少症的治疗进展[J].临床血液学杂志,2020,33(1):6-9.
[33]	Miltiadous O,Hou M,Bussel JB.Identifying and treating refractory ITP:difficulty in diagnosis and role of combination treatment[J].Blood,2020,135(7):472-490.
[34]	Kiessling P,Lledo-Garcia R,Watanabe S,et al.The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration:A randomized phase 1 study[J].Sci Transl Med,2017,9(414):eaan1208.
[35]	Smith B,Kiessling A,Lledo-Garcia R,et al.Generation and characterization of a high affinity anti-human FcRn antibody,rozanolixizumab,and the effects of different molecular formats on the reduction of plasma IgG concentration[J].MAbs,2018,10(7):1111-1130.
[36]	Newland AC,Sánchez-González B,Rejtö L,et al.Phase 2 study of efgartigimod,a novel FcRn antagonist,in adult patients with primary immune thrombocytopenia[J].Am J Hematol,2020,95(2):178-187.